Aldoheptose Biosynthesis. Previously, a novobiocin-hypersensitive mutant of Escherichia coli K-12 carrying a cysE-pyrE linked mutation, designated rfaD, which specifically affects the synthesis of the aldoheptose, L-glycero-D-mannoheptose, has been isolated and genetically characterized. The rfaD gene codes for ADP-L-glycero-D-Mannoheptose-6-epimerase, an enzyme required for lipopolysaccharide (LPS) core biosynthesis. The nucleotide ADP-D-glycero-D-mannoheptose accumulates in rfaD mutant strains. The rfaD phenotype includes increased permeability to a large number of hydrophobic antibiotics, and the formation of mucoid colonies. A 9-kilo-base DNA EcoRI fragment carrying the rfaD gene was initially identified in the Clarke-Carbon Colony Bank cloned in pBR322, and subsequently smaller restriction fragments were cloned into several expression plasmid vectors. RfaD+ plasmids express a protein with a molecular weight of 37,000, and all complement all phenotypes associated with the rfad mutation. Finally ADP-L-glycero-D- mannoheptose-6-epimerase has been purified to homogeneity. Hepatitis Non-A, Non-B. Hepatitis non-A, non-B (HNANB) is a world-wide problem, and 90% of the transfusion-related hepatitis cases in the United States (and 80-90% in several other countries) are diagnosed (by exclusion) as HNANB. Approximately 50% of all acute HNANB patients develop chronic HNANB (an estimate of 4 million persons). Biochemical, immunological, and morphological evidence suggested that the HNANB agent is a mammalian type C retrovirus. Recently, using an in vitro focus-induction assay developed for mammalian type C viruses, we observed that pelleted material from HNANB sera (transfusion-related) induced foci formation. A DNA probe of 780 base pairs isolated from HNANB-infected chimpanzee liver and selected by subtractive hybridization with normal chimpanzee liver was shown to hybridize with liver sections from three HNANB-infected chimpanzees but not with liver from two HBV-infected animals. This DNA fragment has been cloned, completely sequenced, and placed under the control of the Sp6 promoter.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1987
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Morrison, James P; Read, Jay A; Coleman Jr, William G et al. (2005) Dismutase activity of ADP-L-glycero-D-manno-heptose 6-epimerase: evidence for a direct oxidation/reduction mechanism. Biochemistry 44:5907-15
Read, Jay A; Ahmed, Raef A; Morrison, James P et al. (2004) The mechanism of the reaction catalyzed by ADP-beta-L-glycero-D-manno-heptose 6-epimerase. J Am Chem Soc 126:8878-9
Nyan, Dougbeh C; Welch, Anthony R; Dubois, Andre et al. (2004) Development of a noninvasive method for detecting and monitoring the time course of Helicobacter pylori infection. Infect Immun 72:5358-64
Ni, Y; McPhie, P; Deacon, A et al. (2001) Evidence that NADP+ is the physiological cofactor of ADP-L-glycero-D-mannoheptose 6-epimerase. J Biol Chem 276:27329-34
Deacon, A M; Ni, Y S; Coleman Jr, W G et al. (2000) The crystal structure of ADP-L-glycero-D-mannoheptose 6-epimerase: catalysis with a twist. Structure 8:453-62
Ding, L; Zhang, Y; Deacon, A M et al. (1999) Crystallization and preliminary X-ray diffraction studies of the lipopolysaccharide core biosynthetic enzyme ADP-L-glycero-D-mannoheptose 6-epimerase from Escherichia coli K-12. Acta Crystallogr D Biol Crystallogr 55:685-8